Our models
Engineered for the indication. Characterized for the compound.
Each model retains the three-dimensional stromal and hematopoietic microenvironment of the target disease state. Hematopoietic and stromal cell populations are co-cultured at physiologically relevant ratios, then characterized against a defined disease-specific reference panel before release.
One does not fit all. Generic 3D tissue models cannot reproduce the human bone marrow response. Humaniche models are validated against specific disease states so your compound data is comparable, lot to lot.
Select your disease indication
AML Niche Model
MDS Niche Model
Myeloma Niche Model
Aplastic Anemia Model
Stromal architecture recapitulating acute myeloid leukemia. Validated for cytarabine and venetoclax compound screening with lot-to-lot disease-profile characterization.
Recapitulates the dysplastic marrow niche for myelodysplastic syndrome. Suitable for hypomethylating agent screening and clonal evolution studies.
Engineered plasma cell niche for multiple myeloma. Validated for proteasome inhibitor and IMiD compound screening with published stromal characterization per lot.
Hypocellular marrow niche for aplastic anemia toxicology and hematopoietic recovery studies. Lot characterization includes cellularity index and stromal viability metrics.
Modular and plug & play design coming in 3 formats:
Chip format
Syringe format
Well plate format
More information will be made available following patent filing.
Human-Relevant Bone Marrow Models
Know exactly what you need before you order
Input your assay format, replicates, and compound count. The calculator returns the minimum lot quantity required and flags lot-characterization constraints relevant to your study design.
Lot Quantity Calculator - COMING SOON
Ready to run compounds against validated marrow biology?
Contact our team to confirm model availability, discuss lot-to-lot characterization requirements, or initiate a partnership order for your program.
